Lyra Therapeutics Files 8-K

Ticker: LYRA · Form: 8-K · Filed: Jun 9, 2025 · CIK: 1327273

Lyra Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyLyra Therapeutics, INC. (LYRA)
Form Type8-K
Filed DateJun 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, financials

TL;DR

Lyra Therapeutics filed an 8-K on 6/9/25. Nothing major, just standard reporting.

AI Summary

Lyra Therapeutics, Inc. filed an 8-K on June 9, 2025, reporting other events and financial statements. The company, formerly known as Arsenal Medical, Inc., is incorporated in Delaware and headquartered in Watertown, MA.

Why It Matters

This filing provides an update on Lyra Therapeutics' corporate activities and financial reporting, which is important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for other events and financial statements, with no immediate indication of significant negative developments.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Lyra Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of June 9, 2025.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on June 9, 2025.

In which state is Lyra Therapeutics, Inc. incorporated?

Lyra Therapeutics, Inc. is incorporated in Delaware.

What is the principal executive office address for Lyra Therapeutics, Inc.?

The principal executive office address for Lyra Therapeutics, Inc. is 480 Arsenal Way, Watertown, Massachusetts 02472.

Has Lyra Therapeutics, Inc. operated under any former company names?

Yes, Lyra Therapeutics, Inc. has operated under former company names including Arsenal Medical, Inc., Arsenal Vascular, Inc., and 480 Biomedical, Inc.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding Lyra Therapeutics, Inc. (LYRA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing